Home   |   About Us   |   Research & Development   |   Clinical Trials   |   News   |   Contact Us 


  • Mechanistic target of GLY-230 shown to induce changes in retinal cells associated with diabetic retinopathy
  • GLY-230 corrects abnormalities of diabetic retinopathy in experimental diabetes
  • GLY-230 shows efficacy in Phase 2 clinical trial
  • GLY-230 shows positive results in experimental model of Alzheimer's disease
  • CAP22 prevents changes of macrovascular disease in preclinical studies

Glycadia Pharmaceuticals          1880 JFK Blvd, Suite 200          Philadelphia, PA 19103
Tel 215.557.8021          Fax 215.557.8053

Developing safe and effective treatments for diabetic complications.™